FI113779B - Plasmaproteiinien puhdistus - Google Patents
Plasmaproteiinien puhdistus Download PDFInfo
- Publication number
- FI113779B FI113779B FI955306A FI955306A FI113779B FI 113779 B FI113779 B FI 113779B FI 955306 A FI955306 A FI 955306A FI 955306 A FI955306 A FI 955306A FI 113779 B FI113779 B FI 113779B
- Authority
- FI
- Finland
- Prior art keywords
- concentration
- protein
- aqueous phase
- solution
- pct
- Prior art date
Links
- 102000004506 Blood Proteins Human genes 0.000 title claims abstract description 8
- 108010017384 Blood Proteins Proteins 0.000 title claims abstract description 8
- 238000000746 purification Methods 0.000 title description 4
- 239000000126 substance Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 239000003599 detergent Substances 0.000 claims abstract description 17
- 241000700605 Viruses Species 0.000 claims abstract description 16
- 239000008346 aqueous phase Substances 0.000 claims abstract description 16
- 230000000415 inactivating effect Effects 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 14
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 7
- 102000004338 Transferrin Human genes 0.000 claims abstract description 6
- 108090000901 Transferrin Proteins 0.000 claims abstract description 6
- 239000012581 transferrin Substances 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 5
- 102000004411 Antithrombin III Human genes 0.000 claims abstract description 4
- 108090000935 Antithrombin III Proteins 0.000 claims abstract description 4
- 229960005348 antithrombin iii Drugs 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 27
- 229910019142 PO4 Inorganic materials 0.000 claims description 10
- 150000001450 anions Chemical class 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 238000009938 salting Methods 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 abstract description 11
- 108010088751 Albumins Proteins 0.000 abstract description 11
- 238000005191 phase separation Methods 0.000 abstract description 11
- 238000001914 filtration Methods 0.000 abstract description 6
- 238000005185 salting out Methods 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 25
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 239000012629 purifying agent Substances 0.000 description 7
- 239000000693 micelle Substances 0.000 description 6
- -1 alkyl phosphates Chemical class 0.000 description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101001059734 Thermococcus litoralis (strain ATCC 51850 / DSM 5473 / JCM 8560 / NS-C) Trehalose/maltose-binding protein MalE Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/303—Extraction; Separation; Purification by precipitation by salting out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9301582 | 1993-05-07 | ||
| SE19939301582A SE9301582D0 (sv) | 1993-05-07 | 1993-05-07 | Purification of plasma proteins |
| SE9400422 | 1994-05-06 | ||
| PCT/SE1994/000422 WO1994026287A1 (en) | 1993-05-07 | 1994-05-06 | Purification of plasma proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI955306A FI955306A (fi) | 1995-11-06 |
| FI955306A0 FI955306A0 (fi) | 1995-11-06 |
| FI113779B true FI113779B (fi) | 2004-06-15 |
Family
ID=20389869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955306A FI113779B (fi) | 1993-05-07 | 1995-11-06 | Plasmaproteiinien puhdistus |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5817765A (no) |
| EP (1) | EP0700300B1 (no) |
| JP (1) | JP3771935B2 (no) |
| AT (1) | ATE205719T1 (no) |
| AU (1) | AU677332B2 (no) |
| CA (1) | CA2161804C (no) |
| DE (1) | DE69428356T2 (no) |
| DK (1) | DK0700300T3 (no) |
| ES (1) | ES2164702T3 (no) |
| FI (1) | FI113779B (no) |
| NO (1) | NO313084B1 (no) |
| NZ (1) | NZ266234A (no) |
| PT (1) | PT700300E (no) |
| SE (1) | SE9301582D0 (no) |
| WO (1) | WO1994026287A1 (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9500724D0 (sv) | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| ES2099678B1 (es) * | 1995-11-03 | 1998-02-16 | Grifols Grupo Sa | Procedimiento para la inactivacion de virus en proteinas. |
| SE9902388D0 (sv) * | 1999-06-23 | 1999-06-23 | Pharmacia & Upjohn Ab | Method for purification of proteins |
| US6518406B1 (en) | 1999-06-23 | 2003-02-11 | Octapharma Ag | Method for purification of proteins |
| DE19932782A1 (de) * | 1999-07-14 | 2001-01-18 | Biotest Pharma Gmbh | Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung |
| KR20020063597A (ko) * | 1999-12-20 | 2002-08-03 | 미츠비시 웰파마 가부시키가이샤 | 다공성막으로 처리되어 바이러스가 제거된 혈장 단백질조성물 및 그 제조 방법 |
| CA2534900A1 (en) * | 2003-08-12 | 2005-02-17 | Octapharma Ag | Process for preparing an alpha-1-antitrypsin solution |
| CA2572327A1 (en) * | 2004-06-29 | 2006-02-02 | Reliance Life Sciences Pvt. Ltd. | Process for the preparation of virus-safe biological fluids |
| AU2005229674B2 (en) * | 2004-11-18 | 2010-11-04 | Kedrion Melville Inc. | Low concentration solvent/detergent process of immuneglobulin with pre-treatment |
| WO2010033913A1 (en) * | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| CA2742817A1 (en) | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
| CN102812118B (zh) * | 2010-04-08 | 2016-01-20 | 恰根有限公司 | 分离和纯化核酸的方法 |
| EP2395082A1 (en) | 2010-06-14 | 2011-12-14 | QIAGEN GmbH | Extraction of nucleic acids from wax-embedded samples |
| US8921062B2 (en) | 2010-11-09 | 2014-12-30 | Quest Diagnostics Investments Incorporated | Diagnostic and prognostic assays based on circulating tyrosine kinase activity |
| US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
| US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
| US9534029B2 (en) | 2012-10-03 | 2017-01-03 | Csl Behring Ag | Method of purifying proteins |
| WO2014055552A1 (en) * | 2012-10-03 | 2014-04-10 | Csl Behring Llc | A method of purifying proteins |
| US10836790B1 (en) * | 2019-09-20 | 2020-11-17 | Plasma Technologies, Llc | Therapeutic protein compositions and methods |
| US10815270B1 (en) * | 2019-09-20 | 2020-10-27 | Plasma Technologies, Llc | Compositions and methods for high efficiency protein precipitation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US4764369A (en) * | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| US4820805A (en) * | 1983-07-14 | 1989-04-11 | New York Blood Center, Inc. | Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives |
| US4684723A (en) * | 1985-09-11 | 1987-08-04 | Miles Laboratories, Inc. | Method of separating proteins from aqueous solutions |
| US4789545A (en) * | 1986-03-31 | 1988-12-06 | New York Blood Center, Inc. | Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof |
| ATE85221T1 (de) * | 1988-11-05 | 1993-02-15 | Octapharma Ag | Verfahren zur herstellung eines hochreinen, nicht infektioesen antihaemophiliefaktors mittels chromatographie. |
| US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
-
1993
- 1993-05-07 SE SE19939301582A patent/SE9301582D0/xx unknown
-
1994
- 1994-05-06 CA CA002161804A patent/CA2161804C/en not_active Expired - Fee Related
- 1994-05-06 ES ES94915731T patent/ES2164702T3/es not_active Expired - Lifetime
- 1994-05-06 AT AT94915731T patent/ATE205719T1/de active
- 1994-05-06 DE DE69428356T patent/DE69428356T2/de not_active Expired - Lifetime
- 1994-05-06 PT PT94915731T patent/PT700300E/pt unknown
- 1994-05-06 NZ NZ266234A patent/NZ266234A/en not_active IP Right Cessation
- 1994-05-06 EP EP94915731A patent/EP0700300B1/en not_active Expired - Lifetime
- 1994-05-06 JP JP52470494A patent/JP3771935B2/ja not_active Expired - Fee Related
- 1994-05-06 DK DK94915731T patent/DK0700300T3/da active
- 1994-05-06 WO PCT/SE1994/000422 patent/WO1994026287A1/en active IP Right Grant
- 1994-05-06 US US08/537,872 patent/US5817765A/en not_active Expired - Lifetime
- 1994-05-06 AU AU67634/94A patent/AU677332B2/en not_active Ceased
-
1995
- 1995-11-06 NO NO19954428A patent/NO313084B1/no not_active IP Right Cessation
- 1995-11-06 FI FI955306A patent/FI113779B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2161804C (en) | 2003-12-02 |
| NO313084B1 (no) | 2002-08-12 |
| ES2164702T3 (es) | 2002-03-01 |
| AU677332B2 (en) | 1997-04-17 |
| JP3771935B2 (ja) | 2006-05-10 |
| CA2161804A1 (en) | 1994-11-24 |
| DE69428356T2 (de) | 2002-04-25 |
| SE9301582D0 (sv) | 1993-05-07 |
| JPH08509746A (ja) | 1996-10-15 |
| FI955306A (fi) | 1995-11-06 |
| NO954428L (no) | 1995-11-06 |
| ATE205719T1 (de) | 2001-10-15 |
| PT700300E (pt) | 2002-03-28 |
| NZ266234A (en) | 1996-06-25 |
| EP0700300B1 (en) | 2001-09-19 |
| DE69428356D1 (de) | 2001-10-25 |
| WO1994026287A1 (en) | 1994-11-24 |
| FI955306A0 (fi) | 1995-11-06 |
| NO954428D0 (no) | 1995-11-06 |
| DK0700300T3 (da) | 2001-12-31 |
| US5817765A (en) | 1998-10-06 |
| EP0700300A1 (en) | 1996-03-13 |
| AU6763494A (en) | 1994-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI113779B (fi) | Plasmaproteiinien puhdistus | |
| JP3094167B2 (ja) | 免疫血清グロブリンの精製方法 | |
| CA2192683C (en) | Filtration | |
| JP5178518B2 (ja) | 超高収率静注免疫グロブリン製剤 | |
| CN106459140B (zh) | 用于纯化免疫球蛋白的方法 | |
| AU2006287833B2 (en) | An ultra-high yield intravenous immune globulin preparation | |
| DK152334B (da) | Fremgangsmaade til fremstilling af et intravenoest indgiveligt, pyrogenfrit, lagringsstabilt serumproteinpraeparat | |
| JPH04243899A (ja) | 第ｖｉｉｉ因子の精製およびこの方法で得られた第ｖｉｉｉ因子 | |
| KR20190047376A (ko) | 개선된 면역글로불린의 정제방법 | |
| JPH10505753A (ja) | 治療グレードトロンビン産物及び製品 | |
| CN108473530B (zh) | 从血浆中提取蛋白质的方法 | |
| JP4312381B2 (ja) | 濾過によるウイルス的に安全な因子ｖｉｉｉ溶液の調製方法 | |
| CA2077888A1 (en) | Method for purifying factor viii and preparations obtained | |
| KR20020063597A (ko) | 다공성막으로 처리되어 바이러스가 제거된 혈장 단백질조성물 및 그 제조 방법 | |
| CN1105779C (zh) | 一种从生物原料中制备因子ix的方法 | |
| CN1867582A (zh) | 制备α－1－抗胰蛋白酶溶液的方法 | |
| KR20170035980A (ko) | 항체의 정제 방법 | |
| US20210363179A1 (en) | Method for removing fxi when purifying plasma proteins | |
| AU682274C (en) | Filtration | |
| DK1037923T4 (en) | A process for the filtration to produce a solution with regard to virus-safe factor VIII |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |